Aurobindo gains on launch of Cinacalcet Hydrochloride tablets
Aurobindo Pharma has launched Cinacalcet Hydrochloride Tablets (30mg, 60mg and 90mg) in the US market. The shares of Aurobindo Pharma were trading 2 per cent higher on Thursday.
The launch is in accordance with the terms of settlement agreement with Amgen Inc. Aurobindo's Cinacalcet Hydrochloride tablets 30mg, 60mg and 90mg is a generic version of Amgen Inc's Sensipar tablets. According to IQVIA data, Cinacalcet Hydrochloride tablets had an annual sale of approximately US$1,449 million for the twelve months ending May 2019.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
The shares of the company on Thursday opened at Rs. 603.10 against Wednesday’s close of Rs. 597.40. At 14:40 hours, it was trading at Rs. 604, 1.10 per cent higher. The stock's intraday high was Rs. 621.70 and intraday low was Rs. 599.60. Its 52-week high was Rs. 838 and 52-week low was Rs. 566 per share.